Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Neurology ; 73(21): 1792-5, 2009 Nov 24.
Article in English | MEDLINE | ID: mdl-19933982

ABSTRACT

BACKGROUND: Mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) have been implicated in tumorigenesis of gliomas. Patients with high-grade astrocytomas with IDH1 or IDH2 mutations were reported to have a better survival, but it is unknown if this improved survival also holds for low-grade astrocytoma and whether these mutations predict outcome to specific treatment. METHODS: We retrospectively investigated the correlation of IDH1 and IDH2 mutations with overall survival and response to temozolomide in a cohort of patients with dedifferentiated low-grade astrocytomas treated with temozolomide at the time of progression after radiotherapy. RESULTS: IDH1 mutations were present in 86% of the 49 progressive astrocytomas. No mutations in IDH2 were found. Presence of IDH1 mutations were early events and significantly improved overall survival (median survival 48 vs 98 months), but did not affect outcome of temozolomide treatment. CONCLUSION: These results indicate that IDH1 mutations identify a subgroup of gliomas with an improved survival, but are unrelated to the temozolomide response.


Subject(s)
Antineoplastic Agents, Alkylating/therapeutic use , Astrocytoma , Brain Neoplasms , Dacarbazine/analogs & derivatives , Isocitrate Dehydrogenase/genetics , Mutation/genetics , Adult , Antineoplastic Agents, Alkylating/adverse effects , Astrocytoma/drug therapy , Astrocytoma/genetics , Astrocytoma/mortality , Brain Neoplasms/drug therapy , Brain Neoplasms/genetics , Brain Neoplasms/mortality , Cohort Studies , DNA Mutational Analysis , Dacarbazine/adverse effects , Dacarbazine/therapeutic use , Female , Humans , Male , Retrospective Studies , Survival Analysis , Temozolomide , Treatment Outcome
2.
Int J Hyperthermia ; 24(4): 367-75, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18465421

ABSTRACT

BACKGROUND: After observing rather severe acute neurotoxicity in a few patients following deep hyperthermia treatment for a pelvic tumour, we evaluated the incidence of neurotoxicity in all patients treated with deep hyperthermia of the pelvis between June 1990 and April 2004. MATERIALS AND METHODS: Hyperthermia treatment registrations and hospital charts of all 736 patients were reviewed. Differences between the incidence of neurotoxicity in subgroups of patients were evaluated by 2 x 2 exact tests. RESULTS: Grade 2 or 3 acute neurotoxicity occurred in 2.3% of patients, grade 3 in 0.7%. The duration of symptoms was longer than 3 months in 6 patients (0.8%). Neurological examination in 5 patients showed that the most commonly involved structures are the sacral and lower lumbar nerve roots and the sacral plexus. Acute neurotoxicity occurred only after November 1999 and only in patients treated for primary cervical cancer. Comparison of applied powers and achieved temperatures in patients developing neurotoxicity did not show differences between treatment sessions which resulted in neurotoxicity and sessions not resulting in neurotoxicity. CONCLUSION: Acute neurotoxicity following hyperthermia for pelvic tumours is a rare complication, but can result in symptoms affecting the activities of daily life. We found no patient, tumour or treatment characteristics predictive for a risk of neurotoxicity.


Subject(s)
Hyperthermia, Induced , Pelvis , Peripheral Nervous System/pathology , Female , Humans , Incidence , Male
3.
Ned Tijdschr Geneeskd ; 151(15): 874-80, 2007 Apr 14.
Article in Dutch | MEDLINE | ID: mdl-17472120

ABSTRACT

Establishing the presence of paraneoplastic antibodies is important in identifying an often severe neurological syndrome as paraneoplastic and hence directing the search for an underlying neoplasm. A paraneoplastic neurological syndrome was diagnosed in 3 patients. The first was a 64-year-old woman in whom paraneoplastic encephalomyelitis was diagnosed. The diagnosis was strongly supported by a high titre of serum anti-Hu antibodies, despite three negative biopsies from a mediastinal mass. The patient died of a non-convulsive status epilepticus; autopsy revealed not only paraneoplastic encephalomyelitis but also small-cell lung cancer. The second patient was a 55-year-old woman with metastatic breast cancer. After a three-year period of progressive neurological deterioration, a high titre of anti-CV2/CRMP5 antibodies was detected, on the basis of which the clinical syndrome was diagnosed as paraneoplastic. She received immunotherapy and her condition stabilised. The third patient, a 41-year-old man, presented with severe limbic encephalitis. Biopsy from a paraaortic mass was positive for undifferentiated carcinoma. The patient had a high titre ofanti-Ma2 antibodies and was subsequently tested positive for serum alpha-foetoprotein (AFP) and beta-human-chorionic gonadotrophin (bta-HCG). During chemotherapy for a non seminoma testicular cancer, the limbic encephalitis improved both clinically and radiologically, but the patient died as a result of the toxicity of the treatment.


Subject(s)
Antibodies, Neoplasm/analysis , Paraneoplastic Syndromes/diagnosis , Paraneoplastic Syndromes/immunology , Adult , Antibodies, Neoplasm/immunology , Breast Neoplasms/complications , Breast Neoplasms/immunology , Breast Neoplasms/pathology , Carcinoma, Small Cell/complications , Carcinoma, Small Cell/diagnosis , Carcinoma, Small Cell/immunology , Female , Humans , Limbic Encephalitis/complications , Limbic Encephalitis/diagnosis , Limbic Encephalitis/immunology , Lung Neoplasms/complications , Lung Neoplasms/diagnosis , Lung Neoplasms/immunology , Male , Middle Aged , Paraneoplastic Syndromes/etiology , Status Epilepticus/diagnosis , Status Epilepticus/etiology , Status Epilepticus/immunology , Testicular Neoplasms/complications , Testicular Neoplasms/diagnosis , Testicular Neoplasms/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...